Bahrain Oncology Centre Amongst the First in the World to Offer Ground-breaking Sickle Cell and Transfusion Dependent Thalassemia Gene Therapy
May 22, 2024 15:18 ET
|
National Health Regulatory Authority
MUHARRAQ, Bahrain, May 22, 2024 (GLOBE NEWSWIRE) -- The Bahrain Oncology Centre (BOC) has achieved a significant milestone, becoming amongst the first centres in the World to offer the...
Grand River Hospital adopts Intellijoint HIP to study patient and health system benefits through $1 million provincial investment
April 21, 2022 15:22 ET
|
Intellijoint Surgical
Kitchener, Ontario, April 21, 2022 (GLOBE NEWSWIRE) -- The adoption of novel medical technologies in Canada, especially those not supported by available funding models, is extremely challenging....
Isracann Well Positioned for Israel’s Cannabis Sector Growth in 2021
January 19, 2021 09:00 ET
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on...
Axim® Biotechnologies Earns GMP License From Dutch Ministry of Health to Produce Cannabinoid-Based Pharmaceutical Products
October 16, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
New License Allows Leading Cannabinoid Biopharmaceutical Company to Advance Production of Clinical Trial Products NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM®...
Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis
September 23, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...